Bruker Corporation $BRKR Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Bruker Corporation (NASDAQ:BRKR - Free Report) by 5.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 926,790 shares of the medical research company's stock after purchasing an additional 50,537 shares during the period. Charles Schwab Investment Management Inc. owned about 0.61% of Bruker worth $38,684,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BRKR. Raymond James Financial Inc. acquired a new stake in Bruker in the 4th quarter valued at approximately $661,000. Sterling Capital Management LLC increased its holdings in Bruker by 29.0% in the 4th quarter. Sterling Capital Management LLC now owns 3,514 shares of the medical research company's stock valued at $206,000 after purchasing an additional 791 shares during the last quarter. Barclays PLC increased its holdings in Bruker by 58.2% in the 4th quarter. Barclays PLC now owns 88,086 shares of the medical research company's stock valued at $5,164,000 after purchasing an additional 32,401 shares during the last quarter. GeoWealth Management LLC increased its holdings in Bruker by 1,093.9% in the 4th quarter. GeoWealth Management LLC now owns 2,137 shares of the medical research company's stock valued at $125,000 after purchasing an additional 1,958 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Bruker by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,687,364 shares of the medical research company's stock valued at $98,914,000 after purchasing an additional 313,171 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien purchased 2,608 shares of Bruker stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average cost of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 27.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the stock a "hold" rating in a research note on Tuesday, August 5th. UBS Group dropped their price target on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Citigroup dropped their price target on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, August 4th. Bank of America dropped their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Wells Fargo & Company dropped their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Tuesday, August 5th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $51.30.

Bruker Stock Performance

Shares of BRKR stock opened at $33.52 on Monday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average price of $38.99 and a 200 day moving average price of $41.61. The company has a market cap of $5.09 billion, a P/E ratio of 64.46, a PEG ratio of 2.77 and a beta of 1.16. Bruker Corporation has a 12 month low of $30.00 and a 12 month high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%. The business's revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.52 EPS. Sell-side analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be given a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker's payout ratio is 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.